Crinetics Pharmaceuticals (CRNX) Misses Q2 EPS by 7c

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q2 EPS of ($0.94), $0.07 worse than the analyst estimate of ($0.87). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.1 million.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance
• Evolution Petroleum launches stock offering to fund Permian Basin deal